Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling

NCT02037035•Yale University

Summary

This study is looking at the mechanisms underlying the behavioral effects of ketamine in healthy and depressed individuals.

Eligibility

Age

21 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy Group
•Male or female between the ages of 21-65 years.
•Able to provide written informed consent.
•Able to read and write English.
•Male or female between the ages of 21-65 years.
•Able to provide written informed consent.
•Current MDD Single Episode (296.2x) or Recurrent (296.3x), as determined by the Structured Clinical Interview for DSM-IV (SCID) patient edition
•Montgomery Asberg Depression Rating Scale (MADRS) score of 18 or higher at baseline and start of first 13C-MRS.
•Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR16) score of 19 or higher at baseline and start of first 13C-MRS.
•No psychotropic medications for 2 or more weeks (4 weeks for Fluoxetine) prior to first 13C-MRS.
+1 more criteria

Exclusion Criteria

•Personal or first-degree family member with history of mood, anxiety, or psychotic axis I DSM-IV disorders confirmed after comprehensive psychiatric evaluation.
•Any history of serious medical or neurological illness.
•Any signs of major medical or neurological illness on examination or as a result of ECG screening or laboratory studies.
•Lifetime history of psychoactive substance or alcohol dependence or substance or alcohol abuse (other than nicotine or caffeine abuse), or drinking more that 5 drinks/week during the last year.
•Abnormality on physical examination.
•A positive pre-study (screening) urine drug screen or, at the study physician's discretion on any drug screens given before the scans.
•Pregnant or lactating women or a positive urine pregnancy test for women of child-bearing potential at screening or prior to any imaging day.
•Subjects who test positive for HIV or viral hepatitis (hepatitis B and/or C)
•Has received either prescribed or over-the-counter (OTC) centrally active medicine or herbal supplements within the week prior to the MRI scan.
•Any history indicating learning disability, mental retardation, or attention deficit disorder.
+26 more criteria

Locations (1)

Yale Depression Research Program

New Haven, Connecticut, United States

Key Dates

Start Date

July 1, 2013

Primary Completion Date

June 1, 2021

Completion Date

June 1, 2021

Last Updated

September 8, 2021

Enrollment

ACTUAL participants

Conditions

Depression

Interventions

Ketamine

DRUG

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 8, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures